Duchenne Muscular Dystrophy

  • Emflaza 2021 report

    Emflaza 2021 U.S. PROMOTIONAL AUDIT REPORT Published July 2022 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Exondys 51 2021 report

    Exondys 51 2021 U.S. PROMOTIONAL AUDIT REPORT Published July 2022 • 28 Pages The 5 Key Questions Addressed by this...

  • Viltepso 2021 report

    Viltepso 2021 U.S. PROMOTIONAL AUDIT REPORT Published July 2022 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Epclusa 2020 report

    Epclusa 2020 U.S. PROMOTIONAL AUDIT REPORT Published July 2021 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Fibryga 2020 report

    Fibryga 2020 U.S. PROMOTIONAL AUDIT REPORT Published July 2021 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Emflaza 2019 report

    Emflaza 2019 U.S. PROMOTIONAL AUDIT REPORT Published July 2020 • 22 Pages The 5 Key Questions Addressed by this Report:...

  • Exondys 51 2019 report

    Exondys 51 2019 U.S. PROMOTIONAL AUDIT REPORT Published July 2020 • 21 Pages The 5 Key Questions Addressed by this...

  • Emflaza 2018 report

    Emflaza 2018 U.S. PROMOTIONAL AUDIT REPORT Published July 2019 • 24 Pages The 5 Key Questions Addressed by this Report:...

  • Exondys 51 2018 report

    Exondys 51 2018 U.S. PROMOTIONAL AUDIT REPORT Published July 2019 • 21 Pages The 5 Key Questions Addressed by this...

  • Emflaza 2017 report

    Emflaza 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 19 Pages The 5 Key Questions Addressed by this Report:...

  • Exondys 51 2017 report

    Exondys 51 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 21 Pages The 5 Key Questions Addressed by this...